These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside AheadThe Motley Fool • 09/30/25
Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline DepthSeeking Alpha • 09/29/25
Novo, Lilly Weight-Loss Drugs May Help Alzheimer's Patients. What It Means for the Stocks.Barrons • 09/29/25
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer TherapyZacks Investment Research • 09/26/25
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystemPRNewsWire • 09/26/25
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.The Motley Fool • 09/26/25
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's diseasePRNewsWire • 09/25/25
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerPRNewsWire • 09/25/25
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/25/25
Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?The Motley Fool • 09/24/25
Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 09/23/25